Analyst Reco. CureVac N.V. Deutsche Boerse AG

Equities

Real-time Estimate Tradegate Other stock markets 08:43:52 17/06/2024 pm IST			5-day change	1st Jan Change
3.296 ^EUR	-3.17%		-20.24%	-12.76%

28/05	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
28/05	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

CUREVAC : Significant cash drain in the Q1	24/05
CUREVAC : A missed opportunity	03/05
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	26/04	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	25/04	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	22/12	MT
CUREVAC : An untrimmed pipeline becomes costly	29/11
CUREVAC : Unchanged cash drain	28/11
CUREVAC : A missed opportunity	21/23/21
CUREVAC : Higher losses expected in future	25/23/25
CUREVAC : Some glimpse of positive pipeline developments	21/23/21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	08/23/08	MT
CUREVAC : Runway prolonged	30/23/30
CUREVAC : One big point despite many misses	02/23/02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	26/23/26	MT
CUREVAC : Everything hangs on the decision of the new CEO	16/23/16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	19/23/19	MT
CUREVAC : UBS raises its recommendation to Buy	19/23/19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	10/23/10	DJ
Jefferies Upgrades CureVac to Buy From Hold	09/23/09	MT
CUREVAC : Berenberg reaffirms its Buy rating	07/23/07	ZD

No results for this search

CUREVAC : Significant cash drain in the Q1

May 24, 2024 at 01:19 am IST